ENANTA PHARMACEUTICALS INC (ENTA)
Health Care · Biopharmaceuticals / Antiviral therapeutics · NASDAQ
A biotechnology company leveraging small molecule discovery to treat viral and liver diseases, supported by recurring HCV royalty streams.
What ENANTA PHARMACEUTICALS INC does
Enanta Pharmaceuticals is a biopharmaceutical company that develops and commercializes antiviral medications and other therapeutic treatments. The company generates substantially all of its revenue from royalty payments on sales of marketed pharmaceutical products. Enanta is currently unprofitable despite achieving revenue growth, with most operating expenses dedicated to research and development efforts. The company maintains a portfolio of marketed therapies and continues to invest in pipeline advancement.
Themes: viral infectious diseases, respiratory disease therapeutics, small molecule drug development, liver disease research
Fundamentals
- Price$13.47 as of 2026-08-21 close
- Market cap$392M as of 2026-08-21
- 1-year return+56.8% 2025-08-21 close $8.59 → 2026-08-21 close $13.47
- P/En/a negative earnings
- Net margin-96.9% as of 2026-08-24
- ROE-61.8% as of 2026-08-24
- Debt / equity1.25 as of 2026-08-24
- Revenue growth (YoY)+0.7% as of 2026-08-24
- Revenue CAGR (3y)-8.8% SEC XBRL
- Beta0.95 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How ENTA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ENANTA PHARMACEUTICALS INC looks technically
ENANTA PHARMACEUTICALS INC (ENTA) is trading 0.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 20 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 10 trading days ago. It is 21.5% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move. Trading volume is running unusually high — about 2.0× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 0.1% below its 200-day average, the long-term trend line — a long-term downtrend | -0.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.34 | $13.34 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.49 | $13.49 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 13.985. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 20 trading days ago — a "death cross", a bearish long-term signal | 20 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 13.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($12.59 to $13.98) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 63.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.15 | $17.15 |
|---|---|---|
| From the 52-week high | it is 21.5% below its 52-week high (its highest price of the past year) | -21.5% |
| Above the 52-week low | it is 91.1% above its 52-week low (its lowest price of the past year) | +91.1% |
| Below the 52-week high | it is 21.5% below its highest point of the past year | 21.5% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day low about 51 trading days ago | 51 sessions |
| All-time high | its highest closing price on record is $127.77 (set on 2018-07-06) | $127.77 |
| Given back of the 52-week move | over the past year its closes ranged ($7.17 to $16.85), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.56 to $10.87. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.9% |
| From the all-time high | it is 89.5% below its all-time high | -89.5% |
| Nearest price level | it is sitting right on a support level at $13.45 — a price it turned at three times since 2024-08-29, most recently on 2026-03-26. Since 2024-08-21 it has 15 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.2% |
| All-time low | its lowest closing price on record is $4.09 (set on 2025-04-09) | $4.09 |
| Above the all-time low | it is 229.3% above its all-time low | +229.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move | 4th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5989 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5989 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.42 and $13.94 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.42 – $13.18 – $13.94 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is sitting essentially on its 200-day average price (0.1% below it in plain percentage terms) | at its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.0× its 30-day average, a sign of heightened interest | 2.02× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 6.1% above the previous close 49 sessions ago and has not traded back through the level it left behind at 11.07 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.1% |
| Gap filled | a 2.2% gap down opened on 2026-06-23 has been "filled" 42 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 42 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.0 percentage points (the stock gained 0.4% while the market gained 2.3%) | -2.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 5.7 percentage points (the stock lost 2.6% while the market gained 3.1%) | -5.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 11.4 percentage points (the stock lost 0.3% while the market gained 11.1%) | -11.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 36.3 percentage points (the stock gained 56.8% while the market gained 20.5%) | +36.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thin, spanning 1.3% of the share price, which is taken to mean a barrier that gives way easily. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $13.51 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -0.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-10 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $13.33 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +1.1% |
Price levels it has turned at before
ENTA last closed at $13.47 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.45 | Support | 0.2% below the last close | turned there three times · 2024-08-29 to 2026-03-26 |
| $13.11 | Support | 2.7% below the last close | turned there twice · 2026-02-20 to 2026-05-15 |
| $13.98 | Resistance | 3.8% above the last close | turned there twice · 2026-01-20 to 2026-08-13 |
| $12.80 | Support | 5.0% below the last close | turned there twice · 2026-04-24 to 2026-07-15 |
| $15.41 | Resistance | 14.4% above the last close | turned there three times · 2025-09-29 to 2026-07-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $13.98.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Unusually heavy trading volume · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$21.17 range $19.00 – $28.00; median $20.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ENTA
- Consensus EPS estimate-$0.8667 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on royalty revenue from existing HCV partnerships; future revenue may decline.","High risk associated with clinical-stage drug development; failure in clinical trials would significantly harm business.","History of operating losses and requirement for ongoing capital infusions to fund research."]
What changed in the latest 10-Q
AI-assisted comparison of ENTA's 10-Q filed 2026-05-13 against the prior one filed 2026-02-11.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Management's Discussion and Analysis of Financial Condition and Results of Operations page number changed from 16 (filed 2026-02-11) to 17 (filed 2026-05-13)
- Quantitative and Qualitative Disclosures About Market Risk page number changed from 26 (filed 2026-02-11) to 28 (filed 2026-05-13)
- Controls and Procedures page number changed from 26 (filed 2026-02-11) to 28 (filed 2026-05-13)
- Legal Proceedings page number changed from 26 (filed 2026-02-11) to 28 (filed 2026-05-13)
- Notes:
- Only table of contents page numbers are provided in the source texts; actual content changes cannot be assessed from these entries alone
Risk Factors
- Added:
- Newer filing (2026-05-13) includes Item 1A Risk Factors on page 28, Item 5 Other Information on page 28, Item 6 Exhibits on page 29, and Signatures on page 30
- Newer filing includes income tax receivable line item ($19 thousand) in current assets balance sheet as of March 31, 2026
- Newer filing includes long-term marketable securities of $63,238 thousand as of March 31, 2026
- Newer filing includes six-month period financial statements (six months ended March 31, 2026 vs. 2025) in condensed consolidated statements of operations
- Newer filing includes six-month period comprehensive loss statements (six months ended March 31, 2026 vs. 2025)
- Newer filing includes additional stockholders' equity statement section with balances as of March 31, 2026 and March 31, 2025 comparisons
- Removed:
- Older filing (2026-02-11) includes Item 1A Risk Factors on page 26, Item 5 Other Information on page 26, Item 6 Exhibits on page 27, and Signatures on page 28
- Older filing shows balance sheet dated December 31, 2025 and September 30, 2025 (vs. March 31, 2026 and September 30, 2025 in newer filing)
- Older filing shows no income tax receivable line item in balance sheet
- Older filing shows long-term marketable securities of $56,055 thousand as of December 31, 2025 (vs. $63,238 as of March 31, 2026 in newer)
- Older filing condensed consolidated statements of operations show three months ended December 31, 2025 and 2024 (vs. three months and six months ended March 31, 2026 and 2025 in newer)
- Older filing comprehensive loss statements show three months ended December 31, 2025 and 2024
- Older filing stockholders' equity statement shows balances as of December 31, 2025 and December 31, 2024 (vs. March 31, 2026 and March 31, 2025 in newer)
- Older filing includes condensed consolidated statements of cash flows for three months ended December 31, 2025 and 2024 (not present in newer filing excerpt)
- Reworded:
- Page numbering changed: Risk Factors moved from page 26 to page 28, Other Information from page 26 to page 28, Exhibits from page 27 to page 29, Signatures from page 28 to page 30
- Balance sheet comparative periods changed from December 31, 2025/September 30, 2025 to March 31, 2026/September 30, 2025
- Statement of operations comparative periods changed from three months ended December 31, 2025/2024 to three months ended March 31, 2026/2025 and added six-month comparison periods
- Statement of comprehensive loss comparative periods changed from three months ended December 31, 2025/2024 to three months ended March 31, 2026/2025 and added six-month comparison periods
- Stockholders' equity statement changed from ending December 31, 2025 balances to ending March 31, 2026 balances, and from prior year December 31, 2024 comparisons to March 31, 2025 comparisons
- Notes:
- Both filings contain identical forward-looking statements language
- The comparison reflects a transition from Q1 fiscal year 2026 (ended December 31, 2025) to Q2 fiscal year 2026 (ended March 31, 2026) reporting periods
- Financial statement figures themselves are different due to different reporting periods, not text changes within the sections
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ENTA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ENTA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,651,637
- Reported value $58,750,181
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ENTA had 2,587,297 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ENTA had 8.88% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 17.68 days to cover at the same settlement.
- Reported short interest (shares) 2,587,297
- Short interest (% of shares outstanding) 8.88%
- Prior settlement (shares) 2,441,185
- Reported change 5.99%
- Days to cover (reported) 17.68
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- AbbVie (ABBV)
- Vir Biotechnology (VIR)
- Regeneron Pharmaceuticals (REGN)
- Alnylam Pharmaceuticals (ALNY)
- Ionis Pharmaceuticals (IONS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ENTA vs…
Frequently asked questions
What does ENANTA PHARMACEUTICALS INC (ENTA) do?
Enanta Pharmaceuticals is a biopharmaceutical company that develops and commercializes antiviral medications and other therapeutic treatments. The company generates substantially all of its revenue from royalty payments on sales of marketed pharmaceutical products. Enanta is currently unprofitable despite achieving revenue growth, with most operating expenses dedicated to research and development efforts.
What sector is ENANTA PHARMACEUTICALS INC (ENTA) in?
ENANTA PHARMACEUTICALS INC (ENTA) is classified in the Health Care sector. Its industry is Biopharmaceuticals / Antiviral therapeutics. It trades on NASDAQ.
Who are ENANTA PHARMACEUTICALS INC's (ENTA) competitors?
Notable peers of ENANTA PHARMACEUTICALS INC (ENTA) include Gilead Sciences, AbbVie, Vir Biotechnology, Regeneron Pharmaceuticals and Alnylam Pharmaceuticals. This peer set is informational only — not financial advice.
Is ENANTA PHARMACEUTICALS INC (ENTA) overbought or oversold right now?
ENANTA PHARMACEUTICALS INC (ENTA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ENTA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.